Acute lymphoblastic leukemia in adolescents and young adults – from genomics to the clinics

Saad Sirop Kenderian
Mark R Litzow
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA) represents a unique and challenging disease entity. Despite the recent improvement of survival in this population over the last decade, it is still lagging behind the excellent cure rates obtained in pediatric ALL. This special population of AYA receives care from pediatric as well as adult hematologists and can be treated on pediatric or adult protocols. There is a substantial difference in disease biology, response to chemotherapy, and allogeneic stem cell transplantation between pediatric and AYA patients. This review discusses current controversies in the management of AYA, outcomes following treatment with pediatric and adult protocols, and the role of allogeneic stem cell transplantation. It focuses on the unique clinical, biological, and socioeconomic characteristics of this population that might partly explain the inferior outcomes. This review also explores recent advances in genomic profiling and emerging treatments in ALL.

Keywords: novel agents, monoclonal antibodies, stem cell transplantation, bone marrow transplantation, Philadelphia positive ALL, genomic profile

Introduction

Acute lymphoblastic leukemia (ALL) is a heterogeneous group of disorders. The results of clinical trials in adults have been disappointing compared with those of the pediatric age group, with cure rates of 90% in children compared with 30%-40% in adults.1 A recent analysis of the surveillance, epidemiology, and end results (SEER) database showed an improvement in survival in adults over the last two decades, and the greatest significant improvement was in the adolescent group (15–19 years).2,3 However, even in this group, survival is far behind that of children. According to the United States SEER database analysis, the 5-year overall survival (OS) is 87% for children between 0–15 years of age compared with 63% for adolescents and young adults (AYA) between 15–20 years of age. Survival is worse for adults between 20–29 years of age, where the 5-year survival is only 44%.

The reasons for these differences are multifactorial and not fully understood. First of all, AYA patients may be treated by either pediatric or adult hematologists.4,5 Several retrospective analyses have demonstrated superior outcomes when these patients are treated on pediatrics protocols (discussed later in this review). Also, there is a substantial difference in the biology of disease between the adult and pediatric groups (also discussed later in this review). Further, in an analysis by Fern and Whelan,6 less than 2% of adolescents were enrolled in clinical trials compared with over 60% of pediatric patients,6 and poor enrollment in clinical trials has been associated with poor outcomes.7
Heath care delivery in AYA is challenging and complex in the United States, for a variety of reasons. First, there are significant socioeconomic differences between AYA and children. It has been shown that AYA are less likely to comply with treatment plans in general. Treatment protocols for ALL are complex and require significant adherence and patient motivation. Second, this group is the most likely group to be underinsured and is less likely to have health care access. Lastly, there is lack of focused AYA hematologists in the United States.

**Biological factors in ALL in AYA**

Multiple prognostic factors are established in ALL. These include age, white blood cell count at diagnosis, immunophenotype, minimal residual disease (MRD) after induction, and cytogenetics.

One of the substantial differences between children and AYA is the difference in cytogenetics. The genetic abnormalities associated with a good prognosis decrease with age. Hyperdiploidy and the t(12;21) [ETV6/RUNX1] translocation decrease with older age, while poor-risk cytogenetics, such as t(9;22) [BCR/ABL1], complex karyotype, and hypodiploidy, all increase in prevalence with age. In addition to the fact that cytogenetics associated with good prognosis are less common in adults with ALL, multiple analyses have demonstrated that even when present, good risk cytogenetics are associated with inferior survival in adults compared with their counterparts in children. A recent analysis by Burmeister et al has shown that ETV6/RUNX1-rearranged ALL does not have superior outcomes in adult compared with other types of ALL, indicating a possible loss of positive prognostic significance with age. Hyperdiploid cytogenetics were also associated with significantly lower survival in adolescents compared with children. In a recent analysis by Morrice et al, the 5-year event-free survival (EFS) was 87% in children 1–5 years of age, compared with 57% in those 15–18 years old.

In addition to the difference in biological factors between ALL in children and in AYA, there is evidence that adult ALL cells are less susceptible to chemotherapy. In one experiment, cytogenetically identical ALL cells of children older than 10 years were more resistant to chemotherapy in vitro compared with those younger than 10 years. The inferior response to chemotherapy was also observed in multiple clinical trials. In the Children’s Oncology Group (COG) AALL 0232 study, ALL patients between 15–30 years had significantly higher MRD burden compared with children.

This was significant for both standard-risk and poor-risk cytogenetics.

T-cell Acute Lymphoblastic Leukemia (T-ALL) in AYA is also known to be associated with poor outcomes. Recently, the subtype “early T-cell precursor ALL” (ETP-ALL) has been described, characterized by leukemic cells exhibiting expression of cytoplasmic cluster of differentiation (CD)3, weak expression of CD5, absent expression of CD8, CD1a, and aberrant expression of myeloid and stem cell markers. It has been shown that ETP-ALL comprises 10%–15% of childhood and 7.4% of adult T-ALL. ETP-ALL has been associated with poor treatment response, induction failure, and poor EFS and OS, in both pediatric and adult ALL. In both pediatric and adult analyses, ETP-ALL was a frequent presentation in AYA. In one pediatric study, 13 of the 17 pediatric patients (76.5%) with ETP-ALL were between 10–18 years old, and a study of adults found that 27 of the 57 adult patients (47.3%) were 15–35 years old. Table 1 outlines few of the unique biological characteristics of ALL in AYA.

**Genomic profiling in ALL**

Several experiments have shown that recurring chromosomal alterations in ALL are not sufficient to drive the disease or to explain the heterogeneity in response to therapy. Prior to the human genome project, individual mutation were tested using candidate genes, eg, CDKN2A, CDKN2B, and NOTCH.

Since the completion of the human genome projects, multiple groups have sequenced large cohorts with ALL.

| Table 1 Unique biological characteristics of acute lymphoblastic leukemia in adolescents and young adults |
|-----------------|-----------------|
| **Variable**                 | **Discussion**               |
| **Chromosomal alterations in B-ALL** | Lower incidence of low risk cytogenetics hyperdiploidy and t(12;21)                |
| **Prognostic significance** | Higher incidence of poor risk cytogenetics t(9;22), hypodiploidy, complex               |
| **Response to chemotherapy** | Loss of the good prognostic significance of t(12;21)                        |
| **Immunophenotype of T-ALL**  | Hyperdiploidy is associated with inferior outcomes in AYA compared with children          |

Abbreviations: AYA, adolescents and young adults; B-ALL, B cell acute lymphoblastic leukemia; T-ALL, T cell acute lymphoblastic leukemia.
Microarray gene profiling demonstrated distinct gene profiles associated with recurrent chromosomal abnormalities and also identified multiple novel recurring abnormalities in ALL. This review will focus on few of the most common genetic alterations (Figure 1).

Frequency of genetic alterations in different types of ALL
One of the pivotal observations of the human genome project was that two-thirds of ALL is associated with genetic alterations. The frequency of these alterations varied significantly across different types of ALL. For example, MLL-rearranged ALL is associated with very few mutations, which suggests that MLL may be sufficient to induce leukemia. On the other hand, ETV6-RUNX1 mutant ALL harbors many other alterations.

Paired box 5 (PAX5) in ALL
The most common genetic alteration in ALL is PAX5. These mutations are heterozygous and involve focal deletion or translocation and are present in over one-third of patients with ALL. In an analysis of 89 patients with ALL by Iacobucci et al., 29 patients had the PAX5 deletions, and the presence of PAX5 deletions had no prognostic significance in ALL.

Janus kinase 1 and 2 (JAK1 and JAK2) in ALL
JAK mutations are present in up to 35% of Down syndrome–associated ALL and in about 10% of Philadelphia chromosome-positive (Ph+), high-risk pediatric ALL and have been associated with poor outcomes. In one study, the presence of JAK mutations was associated with alteration of IKZF1 and deletion of CDKN2A/B. JAK-mutated ALL had a gene expression profile similar to Ph+ ALL and was associated with poor outcome. In adults, JAK1 mutations were more prevalent in T cell precursor ALL, where they accounted for 18% of cases. Mutations of JAK in adults were associated with a poor response to therapy.

Ikaros family zinc finger protein 1 (IKZF1) in ALL
Alterations of IKZF1 have been significantly associated with poor outcomes in high-risk ALL. Mutations of IKZF1 have been the hallmark of BCR-ABL1-positive ALL and the lymphoid blastic phase of chronic myeloid leukemia (CML). Additionally, these have been associated with poor outcomes in BCR-ABL1-negative ALL, independently of other established prognostic factors. BCR-ABL1-negative, IKZF1 mutant ALL commonly lacks known recurring cytogenetic alterations and has a genomic profile identical to BCR-ABL1-positive ALL.

Cytokine receptor-like factor 2 (CRLF2) in ALL
Alteration involving CRLF2 is another common alteration that is detected in about 5% of adult ALL. CRLF2 is located in the pseudoanatomical region of Xp/Yp, and the alteration typically involves IGH-CRLF2 or P2RY8-CRLF2 rearrangements. Both of these translocations result in abnormal expression in CRLF2 that can be detected by immunohistochemistry. CRLF2-rearranged ALL is associated with mutant JAK2 in up to 50% of cases. In addition to that, almost all cases of JAK1/2 mutant ALL harbor mutations of CRLF2. Several studies attempted to correlate CRLF2 mutation with clinical outcome, with variable results. A recent analysis by the COG concluded that elevated CRLF2 expression was an adverse prognostic feature, even in the absence of rearrangements.

BCR-ABL1-like ALL
About 15%–20% of ALL harbor a gene expression profile similar to that of Ph+ ALL without the BCR-ABL1 translocation. This identifies a genetically distinct subgroup of ALL, called “BCR-ABL1-like ALL.” These cases commonly harbor mutations of the IKZF1. Up to half of these cases also harbor mutations of CRLF2 and/or JAK1/2. A recent analysis assessed the prognostic significance of BCR-ABL1-like...
cases in a cohort of Philadelphia-negative ALL treated in the COG AALL0232 study. In this analysis, the EFS of the BCR-ABL1-like cases was significantly inferior to that of the non-BCR-ABL1 cases (64.1% vs 84.9%) (P < 0.0001). The inferior outcomes persisted after adjusting for age, sex, white blood cells (WBC) at presentation, and MRD after induction. Up to half of cases of BCR-ABL1-like ALL do not have IKZF1, CRLF2, or JAK1/2 mutations. To further understand the genetic basis of these cases, the COG performed whole genome sequencing on 15 of these cases. This identified several novel rearrangements including PDGFRB, ABL1, JAK2, and EPOR. Therefore this data suggests two distinct molecular classes in BCR-ABL1-positive ALL: CRLF2-rearranged and/or JAK1/2 mutant BCR-ABL1-positive ALL, and a second molecular subtype with other rearrangements. The identification of BCR-ABL1-like ALL may have implications in the clinical setting. Preclinical studies have shown that these leukemic cells are sensitive to inhibition with TKIs, suggesting that these patients could be successfully treated with TKIs.

Intrachromosomal amplifications of chromosome 21 (iAMP21) in ALL

iAMP21 is defined as a gain of at least three copies of the RUNX1 region of chromosome 21. In an analysis of 1630 ALL patients treated on the UK MRC ALL97 protocol, iAMP21 was identified in 28 children (2%) and was associated with a significantly inferior EFS (29% vs 78%) and OS (71% vs 87%) at 5 years.

Genetic alterations in relapsed ALL

Genetic mutations in relapsed ALL were found to be different from those at presentation. Alterations of cyclic adenosine monophosphate (cAMP) response-element binding protein were found in about 20% of relapsed ALL cases. It was found more often in relapsed hyperdiploid ALL (60%). These mutations occur almost exclusively in the histone acetyl transferase domain, and they were never present in hyperdiploid ALL patients that remained in long-term remission, indicating a potential mechanism of resistance. There is also recent evidence that mutation of TP53 is more common at relapse.

Genomic profiling of ALL in AYA

To date, there has not been a dedicated study for genomic profiling of AYA with ALL. These patients have been included in both pediatric and adult ALL studies. Therefore, the frequency and prognostic significance of genetic alterations in AYA are not well known. JAK mutations, CRLF2 alteration, and “BCR-ABL-like ALL” profile are among the frequent alterations reported in AYA.

In a study of 187 patients with high-risk Philadelphia chromosome-negative ALL, JAK mutations were reported in 20 patients (10.7%). Out of these 20 patients, 13 were 12–20 years old. The presence of JAK mutations was associated with poor response, and 9 of these 13 patients had a relapsed disease.

Chen et al assessed the frequency of CRLF2, JAK, and IKZF1 in 1061 pediatric patients, comparing high-risk to standard-risk ALL. High-risk disease was defined as age of >10 years or high WBC at presentation. In this analysis, IgH-CRLF2 rearrangements were three times more frequent in the high-risk group (23.8% versus 16.9%).

iAMP21 was also reported in AYA. In an analysis of 1630 patients with ALL, iAMP21 was identified in 28 patients. Of these, 11 (39%) were >10 years. These patients had a significantly lower EFS and OS.

Den Boer et al performed genetic expression studies to assess the frequency and prognostic significance of BCR-ABL-like ALL. The analysis included 190 newly diagnosed pediatric ALL patients enrolled in the German cooperative ALL and was followed by a validation analysis that included 107 patients from the Dutch Childhood Oncology Group (DCOG) protocol. One-third of these patients with BCR-ABL-like ALL were 10 years of age or older.

In summary, AYA ALL patients appear to have a genetic profile similar to patients with high-risk ALL, suggesting that distinct underlying genetic and biologic features account for part of the inferior outcomes observed in AYA. Larger analyses of AYA patients are ongoing.

Treatment of ALL in AYA

The treatment of AYA is challenging, since these patients may be treated by either pediatric or adult hematologists. Multiple recent reviews of this topic have been published. Multiple retrospective analyses have shown survival benefits for patients treated on pediatric protocols compared with adult protocols. One of the largest analyses is a comparison of data from 197 patients treated on a Children’s Cancer Group (CCG) pediatric protocol with that from 124 patients treated on the Cancer and Leukemia Group B (CALGB) adult protocols. The 7-year OS was 67% for patients treated on the CCG protocol compared with 46% in the CALGB protocol.

Boissel et al compared outcomes in ALL patients between the ages of 15–20 years treated on either the pediatric French
Acute Lymphoblastic Leukemia Protocol (FRALLE-93) or the adult France-Belgium Group for Lymphoblastic Acute Leukemia in Adults (LALA-94) protocol. This analysis included 77 AYA enrolled in the FRALLE-93 and 100 in the LALA-94 protocols. Patients were slightly younger in the FRALLE-93 trial. The CR (complete remission) rates were higher when adolescents were treated on the FRALLE-93 protocol (98% versus 81% \(P = 0.002\)), which translated to improvement in EFS \(P < 0.0001\) and the 5-year OS (77% versus 49%) (Figure 2).10

Similar results were obtained in other retrospective analyses and are summarized in Table 2.47–49

A recent meta-analysis of trials comparing AYA patients treated with pediatrics versus adult regimens was conducted.50 This meta-analysis included a total of eleven such trials and 2489 patients. The AYA patients treated on pediatrics regimens had significantly lower all-cause mortality at 3 years (relative risk [RR] 0.58, 0.51–0.67). The number needed to treat to prevent one death was five (95% CI, 4–7). The CR rate was significantly higher when AYA patients received pediatrics regimen (RR 1.05, 1.01–1.1), and there was a significant improvement in the 3-year EFS (RR 1.66, 1.39–1.99).

The reasons for improved outcomes when AYA are treated on pediatric protocols are not clear and likely to be multifactorial. Adult protocols might include more “emancipated minors” who tend to be less compliant with complex protocols, while pediatric protocols are likely to include adolescents who receive treatment under their parents’ supervision. Pediatric protocols include higher doses of nonmyelosuppressive chemotherapy compared with adult protocols, and typically include earlier and more intense intrathecal chemotherapy regimens. Finally, Boissel et al10 noted longer intervals between cycles when AYA were treated on adult protocols. This indicates that pediatric hematologists might follow treatment schedules more strictly compared with adult hematologists.10

The results of these retrospective comparisons have also led to the development of pediatric-inspired prospective trials for adults with ALL.51–53 The Programa Español de Tratamiento en Hematología (PETHEMA) ALL-96 protocol52 included 35 adolescents and 46 young adults. The regimen contained higher cumulative doses of vincristine, steroids, anthracyclines, asparaginase, and cyclophosphamide, and a more intense intrathecal schedule, similar to that in pediatric protocols. The CR rate was 98%. The OS at 6 years was 69%. The other Phase II trials reported similar outcomes.51,53

**Allogeneic stem cell transplantation (SCT) in AYA**

One major difference between adult and pediatric ALL protocols is the wide use of allogeneic SCT in adult trials.

The role of allogeneic SCT in AYA is not clearly defined. There are no prospective trials to evaluate the role of allogeneic SCT specifically in this population. An older retrospective study, from 1995, included patients between the ages of 15–45, from the international bone marrow transplant registry. This showed no survival advantages compared with chemotherapy alone. Transplanted patients had lower relapse rates, but this was offset by the higher transplant-related mortality.54 In a subgroup analysis from the LALA-94 study, there was no survival difference between transplantation and chemotherapy alone in standard-risk patients.55 However, in high-risk patients treated on the LALA-94 protocol, there was a clear benefit of allogeneic SCT over chemotherapy. The disease-free survival (DFS)
was 49% in transplanted patients versus 18% in those treated with chemotherapy alone.56 There were also clear survival advantages in certain high-risk subgroups t(1;19)/E2 A-PBX1 and t(4;11)/MLL-AF4 treated on the LALA-94 study.57 The largest published study evaluating the role of allogeneic SCT in ALL was a joint effort of Medical Research Council (MRC) in Great Britain and Eastern Cooperative Oncology Group (ECOG).58 This trial enrolled nearly 2000 ALL patients and 234 patients younger than 20 years of age. Based on this trial, there was an improvement in the 5-year OS of all patients (53% vs 45%) and of standard-risk patients with Philadelphia-negative ALL (62% vs 52%). The 10-year cumulative relapse rate was 24% when allogeneic SCT was utilized versus 49% when patients were treated with chemotherapy alone.59 However, there was no significant survival advantage in the high-risk group (41% vs 35%) (P = 0.2). The high transplant-related mortality in this group (36%) offset the lower relapse rate in the high-risk group.

One of the major limitations of this study was the use of adult regimens in treating AYA. While allogeneic SCT was associated with survival advantages in adults with standard-risk ALL, the OS in transplanted patients was similar to that in AYA treated on pediatric intensive protocols. Therefore, the use of allogeneic SCT in standard-risk AYA patients remains controversial and warrants further investigation.

**Ph+ ALL**

The Philadelphia chromosome is present in 10%–20% of AYA with ALL. Ph+ ALL has been long recognized as a high-risk ALL with a 5-year OS, prior to the imatinib era, in the range of 20% and a median DFS of less than a year.59 Allogeneic SCT has been widely used for Ph+ ALL in first complete remission (CR-1). Several studies have demonstrated a survival advantage compared with chemotherapy alone. In a subgroup analysis of the LALA-94,60 including only patients with Ph+ ALL, a total of 103 patients were in CR-1 and eligible for transplantation. These patients underwent biological randomization to allogeneic (if a related or unrelated donor was identified) versus autologous SCT and were included in this analysis. Allogeneic SCT was performed in a total of 51 patients in CR-1 compared with 23 patients that received autologous SCT. The 3-year OS was 37% in the donor group and 12% in the no-donor group, indicating a potent graft-versus-leukemia effect in patients with Ph+ ALL.

Since the introduction of TKIs, most protocols now incorporate a BCR-ABL-targeted TKI into combination chemotherapy protocols for Ph+ ALL. Despite the significant improvement in outcomes of Ph+ ALL with the combination protocols, there continues to be a survival advantage for allogeneic SCT. Thomas et al61 reported the MD Anderson Cancer Center experience of combining imatinib with fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone (hyper-CVAD).61 In a recent update of their experience, the 3-year OS was 66% for patients undergoing SCT versus 49% for those treated with imatinib/hyper-CVAD combination. Similar advantages for allogeneic SCT were reported in the Group for Research on Adult Acute Lymphoblastic Leukemia Protocol; GIMEMA, Gruppo Italiano per le Malattie Ematologiche dell’Adulto; GRALL, Group for Research on Adult Acute Lymphoblastic Leukemia; HOvON, Dutch-Belgian Hemato-Oncology Cooperative Group; LALA, France-Belgium Group for Lymphoblastic Acute Leukemia in Adults; LALIN, children with high risk acute lymphoblastic leukemia; MRC, Medical Research Council; NOPHO, Nordic Society for Pediatric Hematology and Oncology; OS, overall survival; RALL, Group for Research on Adult Acute Lymphoblastic Leukemia; SAALLG, Swedish Adult ALL Group; UKALL, United Kingdom Acute Lymphoblastic Leukemia.

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Country</th>
<th>Pediatric protocol</th>
<th>Adult patients</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock et al11</td>
<td>US</td>
<td>197 CCG patients</td>
<td>124 CALGB patients</td>
<td>OS: 67% vs 46%</td>
</tr>
<tr>
<td>Ramanujchar et al68</td>
<td>UK</td>
<td>61 MRC ALL97 patients</td>
<td>67 UKALLXII patients</td>
<td>EFS: 65% vs 49%</td>
</tr>
<tr>
<td>Hallbrook et al67</td>
<td>Sweden</td>
<td>99 SAALLG patients</td>
<td>144 NOPHO ALL92 patients</td>
<td>CR: 99% vs 90%, superior EFS</td>
</tr>
<tr>
<td>De Bont et al67</td>
<td>Netherlands</td>
<td>47 DCOG patients</td>
<td>44 HOVON ALL patients</td>
<td>EFS: 69% vs 34%</td>
</tr>
<tr>
<td>Boissel et al69</td>
<td>France</td>
<td>77 FRALLE patients</td>
<td>100 LALA94 patients</td>
<td>CR: 98% vs 81%, OS: 78% vs 45%</td>
</tr>
<tr>
<td>Usvasalo et al69</td>
<td>Finland</td>
<td>97 Finish Leukemia Group</td>
<td>128 NOPHO ALL patients</td>
<td>EFS: 67% vs 60% ( P = NS )</td>
</tr>
<tr>
<td>Huguet et al51</td>
<td>France</td>
<td>214 GRALL 2003 patients</td>
<td>712 LALA94 patients</td>
<td>EFS: 57% vs 33%, OS: 61% vs 41%</td>
</tr>
<tr>
<td>Lopez-Hernandez et al86</td>
<td>Mexico</td>
<td>20 LALIN patients</td>
<td>20 LALA patients</td>
<td>EFS: 70% vs 40%</td>
</tr>
<tr>
<td>Alves et al89</td>
<td>Brazil</td>
<td>34 BFM 90/95 patients</td>
<td>11 BFM 64 patients</td>
<td>OS: 68.6% vs 31.4%</td>
</tr>
<tr>
<td>Haiat et al100</td>
<td>France</td>
<td>28 FRALLE-2000 patients</td>
<td>20 EORTC ALL-4 patients</td>
<td>OS: 83% vs 35%</td>
</tr>
<tr>
<td>Testi et al101</td>
<td>Italy</td>
<td>150 AIEOP ALL 95/2000 patients</td>
<td>95 GIMEMA ALL patients</td>
<td>OS: 80% vs 71%</td>
</tr>
</tbody>
</table>

**Abbreviations:** AIEOP, Associazione Italiana Ematologia Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster; CALGB, Cancer and Leukemia Group B; CCG, Children’s Cancer Group; DCOG, Dutch Childhood Oncology Group; EFS, event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FRALLE, French Acute Lymphoblastic Leukemia Protocol; GIMEMA, Gruppo Italiano per le Malattie Ematologiche dell’Adulto; GRALL, Group for Research on Adult Acute Lymphoblastic Leukemia; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; LALA, France-Belgium Group for Lymphoblastic Acute Leukemia in Adults; LALIN, children with high risk acute lymphoblastic leukemia; MRC, Medical Research Council; NOPHO, Nordic Society for Pediatric Hematology and Oncology; OS, overall survival; RALL, Group for Research on Adult Acute Lymphoblastic Leukemia; SAALLG, Swedish Adult ALL Group; UKALL, United Kingdom Acute Lymphoblastic Leukemia.
Lymphoblastic Leukemia protocol (GRAAPH-2003) and the Italian trial. These reports suggest that patients with Ph+ ALL continue to benefit from a potent graft-versus-leukemia effect in the era of imatinib and other TKIs, and by improving the response rates, more patients are able to proceed with allogeneic SCT. These studies have also shown that the prognosis of Ph+ ALL has significantly improved with the addition of TKIs. The combinations of hyper-CVAD/TKI were superior to historic controls from LALA-94 and other studies in the pre-TKI era. The UKALL/ECOG2993 trial recently reported an improved 3-year OS of 42% after the addition of imatinib to treatment compared with the OS of 25% reported in the pre-imatinib era. Since the emergence of multiple BCR-ABL mutations, several clinical trials have investigated the combination of chemotherapy with second generation TKIs. Dasatinib was combined with hyper-CVAD, and the combination resulted in high CR rates (94%) and a 2-year OS of 64%.

One of the most frequent gate keeper mutations is T315I, which is resistant to imatinib and second-generation TKIs. Ponatinib is a potent oral TKI that was shown to overcome this mutation in vitro. A Phase I study of single-agent oral ponatinib in CML and Ph+ ALL was recently reported. Of the 22 patients with accelerated phase CML, blast phase CML, or Ph+ ALL treated on this study, 36% had a major hematological response, and 32% had a major cytogenetic response. The combination of ponatinib with chemotherapy in frontline treatment of Ph+ ALL warrants further investigations.

**Novel therapies in ALL**

Although intensified chemotherapy regimens have improved outcomes in AYA as noted earlier in this review, these regimens are not tolerated well by older adults with ALL. Over the past decade, several new modalities in the treatment of ALL have emerged and/or are emerging that may allow for improved responses and outcomes for older and younger patients with ALL. The different approaches include combinations of agents already approved for other disease, novel monoclonal antibodies, small molecule TKIs, and monoclonal antibodies conjugated to immunotoxins. Multiple recent reviews of these therapies have been published. This section will outline a few of the promising agents in ALL; these are also summarized in Table 3.

**Monoclonal antibodies**

**Rituximab**

Prognostic significance of CD20 expression in ALL

The prognostic significance of CD20 in ALL is controversial. CD20 is a B lymphocyte-specific integral

<table>
<thead>
<tr>
<th>Table 3 Novel agents in acute lymphoblastic leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agent</strong></td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Rituximab</td>
</tr>
<tr>
<td>Blinatumomab</td>
</tr>
<tr>
<td>Alemtuzumab</td>
</tr>
<tr>
<td>Epratuzumab</td>
</tr>
<tr>
<td>Inotuzumab ozogamicin</td>
</tr>
<tr>
<td>Moxetumomab pasudotox</td>
</tr>
<tr>
<td>Decitabine</td>
</tr>
<tr>
<td>Clofarabine</td>
</tr>
<tr>
<td>Nelarabine</td>
</tr>
</tbody>
</table>

**Abbreviations:** ara-G, 9-β-D-arabinofuranosylguanine; ALL, acute lymphoblastic leukemia; B-ALL, B cell acute lymphoblastic leukemia; CD, cluster of differentiation; CR, complete remission; CVAD, cyclophosphamide, vincristine, Adriamycin, and dexamethasone; DFS, disease free survival; mAb, monoclonal antibody; OS, overall survival; T-ALL, T cell acute lymphoblastic leukemia.
membrane phosphoprotein. It is expressed in 30%–40% of B-precursor ALL and 80%–90% of mature B cell ALL (B-ALL). While some studies have shown this to have a negative prognostic significance and negative impact on outcomes,49 others failed to show such a difference,50 and at least one study detected a difference in high-risk patients only.71 Another recent study has shown that the negative prognostic impact of CD20 is lost after allogeneic SCT.72 This might be related to the advances in treatment of childhood ALL and to the improvement in survival and outcomes.

Rituximab in mature B-ALL and Burkitt-like ALL

The success of rituximab in non-Hodgkin lymphoma (NHL) and an improvement in survival of >20% was the basis for assessing the role of rituximab in ALL. Several studies have evaluated the addition of rituximab in mature B-ALL or Burkitt’s ALL. The GMALL (German Multicentre Study Group for Adult ALL) initiated the protocol ALL/NHL2002, which used rituximab plus chemotherapy. In this regimen, rituximab was given on day 1 of each cycle, for a total of eight doses. The most recent update included 277 patients treated on this protocol. The OS was 88% for Burkitt’s NHL and 70% for mature B-ALL.73,74 The MD Anderson Cancer Center study examines the addition of rituximab to the hyper-CVAD regimen. In a recent update of 51 patients treated on this combination, the CR rate was 95% and 4-year OS was 77% compared with 50% from a prior MD Anderson experience of hyper-CVAD without rituximab. The survival benefits were more pronounced in patients over 60 years old.75,76

Based on these positive studies, the combination of rituximab and chemotherapy has become the standard of care in mature B-ALL or Burkitt-like ALL.

Rituximab in precursor B-ALL

The combination of rituximab with chemotherapy in pre-B-ALL was evaluated by multiple groups. The MD Anderson group used the combination of hyper-CVAD and rituximab in 173 patients. The overall CR rate was 95%, and the 3-year OS was 50%. Compared with historic controls that were treated without rituximab, there was significant improvement in survival in younger patients (<60 years old) with CD20-positive ALL, with an OS of 75% vs 46% in historic controls. There did not appear to be any survival advantages in patients older than 60 years with CD20-negative ALL.77 The GMALL 07/200378 experience was similar. In their study, the addition of rituximab was associated with survival advantages compared with survival in historic controls, in patients younger than 55 years. These two studies suggest the addition of rituximab was associated with improved outcomes in younger patients with CD20-positive pre-B-ALL. The role of rituximab in older patients with pre-B-ALL remains controversial and is currently being tested in randomized clinical trials.

Blinatumomab

CD19 is virtually expressed on all ALL cells. Blinatumomab is an antibody that works by constructing a bispecific T-cell-engaging antibody construct. It combines an anti-CD19 antibody and an anti-CD3 antibody, and links T cells and malignant B cells by recruiting CD3-positive T cells to lyse CD19-expressing B cells. The clinical safety of blinatumomab was studied in a Phase I study with 38 patients with non-Hodgkin lymphoma. The drug was found to be tolerable and eleven major responses were noted.79 A Phase II clinical trial in refractory ALL80 was recently updated. Blinatumomab was given by continuous infusion for 28 days, followed by 14-day treatment-free intervals. Responders had the option of receiving three more cycles or proceeding to allogeneic SCT. A total of 36 patients were treated in this clinical trial. Of these, 26 (72%) achieved CR or CR with partial hematological recovery. Twenty four (92%) out of these 26 responders also achieved molecular response. The rate of CR was 100% in patients in first relapse (21 of 21 patients in first relapse had a CR). Of the 26 responders, 13 proceeded to allogeneic SCT, and one of these patients relapsed. The other 13 did not undergo allogeneic SCT and eight of them relapsed. The median OS for the whole cohort was 9.0 months, with a median survival of 14.1 months in responders compared with 6.6 months in nonresponders. Common toxicities included cytokine release syndrome and reversible CNS toxicity (seizures or encephalopathy). This study shows high CR rates and promising clinical activity with blinatumomab. Larger studies are ongoing.

Alemtuzumab

Alemtuzumab has been approved for benign and malignant hematological diseases, including chronic lymphocytic leukemia (CLL). A CALGB trial (CALGB 10102) evaluated the role of maintenance alemtuzumab in ALL and was recently updated.81 All patients were in CR-1, and eligible patients had more than 10% expression of CD52 on lymphoblasts at diagnosis. A total of 24 patients were treated on this protocol. Therapy consisted of 6 months of chemotherapy followed by 2 years of maintenance alemtuzumab. There was a median of one log reduction in MRD measurements in the group that received 20 mg and
30 mg subcutaneously. One patient had a two log increase and relapsed after 6 weeks. The median DFS for this cohort was 53 months. The authors of this study concluded that since CD52 is expressed on ALL lymphoblasts, alemtuzumab is a potential therapeutic option.

**Epratuzumab**
Epratuzumab is a fully humanized monoclonal antibody directed against CD22. CD22 is expressed in over 90% of ALL blasts. Epratuzumab was studied in pediatric patients with relapsed ALL. The initial report consisted of a twice-weekly dose schedule for four doses as a single agent, followed by four weekly doses in combination with standard chemotherapy. Of 15 patients, two had dose-limited toxicities, which were a grade 4 seizure and an asymptomatic alanine aminotransferase (ALT) elevation. Nine patients achieved CR after the combination and seven were MRD-negative. A recent study (Southwest Oncology Group (SWOG) S0910) investigated the combination of cytarabine, clofarabine, and epratuzumab in relapsed refractory ALL. Thirty-five patients were enrolled, and three were ineligible. All of these patients were heavily pretreated and four had received prior allogeneic SCT. In the 32 evaluable patients, the response rate was 45% (including CR and CR with inadequate counts recovery). The median OS was 4 months. The authors concluded that the addition of epratuzumab had clinical benefits in the relapsed refractory settings.

**Inotuzumab ozogamicin**
Inotuzumab is a monoclonal antibody against CD22, conjugated to the toxin calicheamicin. It was evaluated in refractory lymphomas with impressive results. In a Phase II study in relapsed and refractory ALL, inotuzumab ozogamicin was initially given in a dose of 1.3 mg/m² every 3–4 weeks. After the first 49 patients were treated, the dose was modified to three weekly inotuzumab doses every 3–4 weeks.

A total of 83 patients were treated. The CR rate was 17%; CR with no platelet recovery was found in 28%, and 11% had marrow CR, with no recovery of counts. Most patients achieving CR also had cytogentic CRs. Forty-four responders had MRD measurements, and all converted to MRD negativity. The overall response rate was 57% with the single dose and 53% with the weekly dose regimens. The median survival was 5 months with the single-dose and 6.3 months with the weekly-dose regimens. Allogeneic SCT was performed in 49% of patients treated on single dose and in 26% of patients treated on weekly doses. The most common side effects were transient elevation of liver function tests.

**Monoclonal antibodies conjugated to immunotoxins**
BL22 (CAT-3888) is an anti-CD22 immunotoxin composed of a variable fragment of the CD22 monoclonal antibody fused with a 38 kDa fragment of *Pseudomonas aeruginosa* endotoxin A. After promising preclinical data, a Phase I study was conducted and recently reported. Of the 23 patients enrolled in this study, 70% had reductions in blast count and four patients had more than a 2 log reduction in blast count. There were no objective CRs or partial responses. A newer version of BL22 is called high affinity BL22 (HA-22) or moxetumomab pasudotox. It has a 145-fold increased binding affinity for CD22 compared with CAT-3888 and higher activity against CD22-positive hematological malignancies in vitro. Moxetumomab has also been shown to have significant activity in refractory hairy cell leukemia. In pediatric ALL, 21 patients were recently treated with moxetumomab in a Phase I dose-escalating study. The drug was tolerated up to doses of 40 mcg/kg every other day for six doses. The most common toxicities included elevation in liver function tests. In the 17 evaluable patients, the objective response rate was 29%, including 24% CR rate. In addition to that, a hematological improvement in counts was noted in 41% of patients. Based on this observed clinical activity, the drug is being evaluated in Phase II studies.

**Decitabine**
Preclinical experiments have shown that hypermethylation of the promoter region of tumor suppressor genes has a major role in leukemic transformation in ALL. Also, exposure of ALL cell lines to decitabine resulted in induction of apoptosis via hypomethylation. A Phase 1 trial combining decitabine with or without hyper-CVAD in ALL was recently reported. The trial was designed in such a way that patients were treated with single-agent decitabine first. Nonresponders continued on with the sequential phase of the trial and received a combination of hyper-CVAD and decitabine. The initial dose of single-agent decitabine used was 10 mg/m² intravenously, with dose levels ranging between 10 to 120 mg/m² daily for 5 days. A dose level of 60 mg/m² daily for 5 days every 2 weeks was selected as the optimal dose. When combined with hyper-CVAD, the initial dose was 5 mg/m² daily, with dose levels up to 60 mg/m². A dose level of 40 mg/m² was selected as the optimal dose level in combination with hyper-CVAD. Treatment was given for 5 days on a 28-day cycle.
In total, 39 patients were treated. In patients treated with single-agent decitabine, 23% achieved complete marrow responses. With the combination of decitabine with hyper-CVAD, the overall response rate was 52% with a complete marrow response of 28%. Based on this trial, investigators concluded that decitabine has single-agent activity and that the combination with hyper-CVAD is safe and active. Large-scale clinical trials are ongoing.

**Clofarabine**

Clofarabine is a novel deoxyadenosine analogue that was recently approved for relapsed ALL in children. The pivotal Phase II trial led to its approval included 61 patients with refractory or relapsed ALL. The clofarabine dose was 25 mg/m², given for 5 days and repeated every 2–6 weeks. The overall response rate was 30%, with a CR rate of 12%. Remissions were durable, and nine patients proceeded to allogeneic SCT. The most common grade 3 adverse event was febrile neutropenia. The activity of clofarabine in ALL was validated in other studies, in both pediatrics and adults.

Based on these clinical trials, clofarabine is currently a widely used agent in relapsed ALL.

**Nelarabine**

Nelarabine is a deoxyguanosine derivative and a soluble prodrug of 9-B-D-arabinofuranosylguanine (ara-G). It was recently approved for patients with relapsed T-ALL and T cell acute lymphoblastic lymphoma who have failed prior two regimens. The major Phase II study included 39 patients with refractory disease (13 with T cell lymphoblastic lymphoma and 26 patients with T-ALL). Nelarabine was given 1.5 g/m² on days 1, 3, and 5. Treatment was repeated every 22 days. Seventy-two percent had more than one prior course of chemotherapy, and 13% had prior allogeneic SCT. The complete remission rate in this heavily pretreated group of patients was 31%, and the overall response rate was 41%. The duration of response was 22 weeks. Seven patients received allogeneic SCT following treatment with nelarabine. The main toxicities were myelosuppression and neurological toxicities. The 1-year OS was 28%. Another Phase II study was recently reported by the German group with similar outcomes. Nelarabine was also incorporated in the frontline therapy of patients with T-ALL. A total of 36 patients were treated on a recently reported Phase II study. Nelarabine was administered at a dose of 650 mg/m² for two cycles during the intensified consolidation. The CR rate was 91.6%, and 5% of patients had a partial response. Molecular CR was achieved in 53% of patients with T-ALL. After a 19-month follow-up, 58.3% of patients were alive and in complete remission. The probability of CR at 3 years was estimated to be 66%. The most common grade 3 adverse event with this combination was infection. The authors concluded that the upfront combination of nelarabine with chemotherapy is safe and is associated with high rates of molecular complete remissions.

**Role of novel therapies in AYA**

While there are no prospective clinical trials of novel therapy combinations in AYA, these patients are frequently enrolled in adult ALL trials.

AYA patients were included in the blinatumomab, alemtuzumab, and epratuzumab early studies, but subgroup analyses were not feasible due to the small sample size. In precursor CD20-positive ALL, patients younger than 30 years of age have been found to experience the most benefit from the addition of rituximab to hyper-CVAD therapy. The response rate was 99% and 3-year OS was 70%, significantly higher than what was reported in older patients.

In the initial report of inotuzumab ozogamicin, ten of the 42 patients enrolled in the Phase II study were between 13–25 years of age. The drug was active in this group, with an overall response/response without counts recovery of 30%. Twelve of the 23 patients treated with moxetumomab were AYA. While no responses were observed in the whole cohort, the investigators reported transient clinical activity in ten of the 12 (83.3%) AYA patients.

Clofarabine has also been shown to be active in AYA with relapsed ALL. In the pivotal Phase II trial that included 61 patients, ten out of the 18 responders were AYA. Eight of them had a CR or CR without platelet recovery, two had a partial response and three underwent subsequent SCT.

AYA patients with relapsed T-ALL were also included in the Phase II studies of nelarabine. In the German trial, 35 patients between 15–25 years old were included. The investigators reported significant activity for nelarabine in patients younger than 45 years of age (CR 37%, 3-year survival 16%).

This indicates that AYA ALL patients benefit from novel therapy combinations, which in turn might lead to a significant improvement in their response rates and outcomes. Larger clinical trials are ongoing.

**Conclusion**

AYA with ALL continue to represent a challenging group of patients with unique biological and socioeconomic characteristics. ALL, in this population, is associated with an increased incidence of unfavorable cytogenetics and an inferior
response to chemotherapy. These patients have superior survival when treated on pediatric intense protocols. AYA with high-risk ALL seem to benefit from a potent graft-versus-leukemia effect, while the role of allogeneic SCT in standard-risk ALL is unclear. The addition of imatinib and other TKIs has improved outcomes in Ph+ ALL, but there continues to be survival advantages for allogeneic SCT in the era of TKIs. The introduction of novel therapies has led to significant advances in ALL management. Rituximab has become the standard of care in mature ALL and is being investigated in larger clinical trials in precursor ALL. Clofarabine is approved for relapsed ALL, and nelarabine is associated with high response rates in relapsed refractory T-ALL and is FDA-approved for this indication. Other promising highly effective therapies include blinatumomab, epratuzumab, and inotuzumab ozogamicin. Several molecular abnormalities were described in ALL and may become important drug targets.

Disclosure
Mark R Litzow received consulting fees and research funding from Amgen. The authors report no other conflicts of interest in this work.

References


